These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 20079359)
21. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Kitada M; Koya D; Sugimoto T; Isono M; Araki S; Kashiwagi A; Haneda M Diabetes; 2003 Oct; 52(10):2603-14. PubMed ID: 14514646 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of protein kinase Cbeta protects against diabetes-induced impairment in arachidonic acid dilation of small coronary arteries. Zhou W; Wang XL; Lamping KG; Lee HC J Pharmacol Exp Ther; 2006 Oct; 319(1):199-207. PubMed ID: 16861398 [TBL] [Abstract][Full Text] [Related]
23. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. Koya D; Haneda M; Nakagawa H; Isshiki K; Sato H; Maeda S; Sugimoto T; Yasuda H; Kashiwagi A; Ways DK; King GL; Kikkawa R FASEB J; 2000 Mar; 14(3):439-47. PubMed ID: 10698958 [TBL] [Abstract][Full Text] [Related]
24. Protein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic rats. Wu Y; Wu G; Qi X; Lin H; Qian H; Shen J; Lin S J Pharmacol Sci; 2006 Aug; 101(4):335-43. PubMed ID: 16891764 [TBL] [Abstract][Full Text] [Related]
25. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. McGill JB; King GL; Berg PH; Price KL; Kles KA; Bastyr EJ; Hyslop DL Expert Opin Drug Saf; 2006 Nov; 5(6):835-45. PubMed ID: 17044810 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Aiello LP; Clermont A; Arora V; Davis MD; Sheetz MJ; Bursell SE Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):86-92. PubMed ID: 16384948 [TBL] [Abstract][Full Text] [Related]
27. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002 [TBL] [Abstract][Full Text] [Related]
28. Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Yuan SY; Ustinova EE; Wu MH; Tinsley JH; Xu W; Korompai FL; Taulman AC Circ Res; 2000 Sep; 87(5):412-7. PubMed ID: 10969040 [TBL] [Abstract][Full Text] [Related]
30. Counter regulatory effects of PKCbetaII and PKCdelta on coronary endothelial permeability. Gaudreault N; Perrin RM; Guo M; Clanton CP; Wu MH; Yuan SY Arterioscler Thromb Vasc Biol; 2008 Aug; 28(8):1527-33. PubMed ID: 18497307 [TBL] [Abstract][Full Text] [Related]
31. Activation of protein kinase C and disruption of endothelial monolayer integrity by sodium arsenite--Potential mechanism in the development of atherosclerosis. Pereira FE; Coffin JD; Beall HD Toxicol Appl Pharmacol; 2007 Apr; 220(2):164-77. PubMed ID: 17306850 [TBL] [Abstract][Full Text] [Related]
32. Glycogen synthase kinase 3 inhibitor protects against microvascular hyperpermeability following hemorrhagic shock. Sawant DA; Tharakan B; Hunter FA; Childs EW J Trauma Acute Care Surg; 2015 Oct; 79(4):609-16. PubMed ID: 26402535 [TBL] [Abstract][Full Text] [Related]
33. Hyperglycaemia promotes cerebral barrier dysfunction through activation of protein kinase C-β. Shao B; Bayraktutan U Diabetes Obes Metab; 2013 Nov; 15(11):993-9. PubMed ID: 23617822 [TBL] [Abstract][Full Text] [Related]
35. Erythropoietin maintains VE-cadherin expression and barrier function in experimental diabetic retinopathy via inhibiting VEGF/VEGFR2/Src signaling pathway. Liu D; Xu H; Zhang C; Xie H; Yang Q; Li W; Tian H; Lu L; Xu JY; Xu G; Liu K; Sun X; Xu GT; Zhang J Life Sci; 2020 Oct; 259():118273. PubMed ID: 32800831 [TBL] [Abstract][Full Text] [Related]
36. PKC-B inhibition: a new therapeutic approach for diabetic complications? Avignon A; Sultan A Diabetes Metab; 2006 Jun; 32(3):205-13. PubMed ID: 16799396 [TBL] [Abstract][Full Text] [Related]
37. Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Kowluru RA; Jirousek MR; Stramm L; Farid N; Engerman RL; Kern TS Diabetes; 1998 Mar; 47(3):464-9. PubMed ID: 9519755 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of protein kinase C βII isoform rescues glucose toxicity-induced cardiomyocyte contractile dysfunction: role of mitochondria. Wang Z; Zhang Y; Guo J; Jin K; Li J; Guo X; Scott GI; Zheng Q; Ren J Life Sci; 2013 Jul; 93(2-3):116-24. PubMed ID: 23770211 [TBL] [Abstract][Full Text] [Related]
39. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Kowluru RA Acta Diabetol; 2001 Dec; 38(4):179-85. PubMed ID: 11855796 [TBL] [Abstract][Full Text] [Related]
40. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin. Brooks B; Delaney-Robinson C; Molyneaux L; Yue DK J Diabetes Complications; 2008; 22(2):88-95. PubMed ID: 18280438 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]